Our recent findings indicate that IFN-DC loaded ex vivo or in vivo with whole-tumor cell lysates are promising candidates for cancer vaccination, particularly effective in cross-presentation of tumor-associated antigens to CD8 T-cells and in their expansion [17,44,45]. This evidence concerns the gene IFNA1 and neoplasm.